Aliases & Classifications for Muscle Cancer

MalaCards integrated aliases for Muscle Cancer:

Name: Muscle Cancer 12 51 14
Myosarcoma 12 51 41 69
Malignant Neoplasm of Muscle 12 69
Malignant Tumor of the Muscle 12
Malignant Tumor of Muscle 12
Myomatous Neoplasm 69
Muscle Neoplasms 41

Classifications:



External Ids:

Disease Ontology 12 DOID:4045
ICD10 32 C49
NCIt 46 C4883

Summaries for Muscle Cancer

Disease Ontology : 12 A musculoskeletal system cancer that is located in muscle.

MalaCards based summary : Muscle Cancer, also known as myosarcoma, is related to skeletal muscle cancer and leiomyosarcoma, and has symptoms including myalgia, muscle weakness and torticollis. An important gene associated with Muscle Cancer is PAX3 (Paired Box 3), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Cyclophosphamide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include muscle, bone and nk cells, and related phenotypes are cellular and growth/size/body region

Wikipedia : 72 A soft-tissue sarcoma is a form of sarcoma that develops in connective tissue, though the term is... more...

Related Diseases for Muscle Cancer

Diseases related to Muscle Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
# Related Disease Score Top Affiliating Genes
1 skeletal muscle cancer 32.0 EWSR1 FOXO1 KIDINS220 MB MYOD1 MYOG
2 leiomyosarcoma 30.2 DES KIT MB MDM2 MYOG PGR
3 rhabdomyosarcoma 29.9 DES EWSR1 FOXO1 MB MDM2 MYOD1
4 lymphangiomatosis 10.6 DES PGR
5 lung leiomyoma 10.6 MB PGR
6 endometrium carcinoma in situ 10.6 PGR TP53
7 ovarian fibrothecoma 10.6 DES KIT
8 prostate embryonal rhabdomyosarcoma 10.6 KIT MYOD1
9 vestibular gland benign neoplasm 10.6 PGR TP53
10 bartholin's gland adenoma 10.6 PGR TP53
11 giant cell myocarditis 10.6 DES MB
12 striated muscle rhabdoid tumor 10.6
13 orbit rhabdomyosarcoma 10.6 MB MYOG
14 ectomesenchymoma 10.6 DES PAX3
15 cervical polyp 10.6 DES MYOD1
16 malignant triton tumor 10.5 DES MB MYOD1
17 spindle cell rhabdomyosarcoma 10.5 DES MB MYOD1
18 perivascular epithelioid cell tumor 10.5 DES KIT PGR
19 testicular gonadoblastoma 10.5 KIT WT1
20 epulis 10.5 DES PGR
21 smooth muscle tumor 10.5 DES KIT PGR
22 vulvar benign neoplasm 10.5 CALD1 PGR
23 cerebellar angioblastoma 10.5 TP53 WT1
24 vulvar leiomyoma 10.5 CALD1 PGR
25 ring chromosome 7 10.5 MDM2 TP53
26 angiomyolipoma 10.5 DES KIT PGR
27 breast malignant phyllodes tumor 10.5 PGR TP53
28 spindle cell lipoma 10.5 DES FOXO1 MDM2
29 prostate stromal sarcoma 10.5 CD34 PGR
30 uterine body mixed cancer 10.5 KIT PGR TP53
31 esophagus sarcoma 10.5 CREB3L2 KIT
32 actinic cheilitis 10.5 MDM2 TP53
33 uterine carcinosarcoma 10.5 KIT PGR TP53
34 endosalpingiosis 10.5 PGR WT1
35 olfactory groove meningioma 10.4 PGR TP53
36 central nervous system mesenchymal non-meningothelial tumor 10.4 FOXO1 MYOD1 PAX3 PAX7
37 gallbladder leiomyoma 10.4 CD34 KIT
38 lung leiomyosarcoma 10.4 CD34 KIT
39 malignant fibroxanthoma 10.4 DES MDM2 MYOD1
40 orbital cancer 10.4 EWSR1 MB
41 trigonitis 10.4 CD34 PGR
42 kidney clear cell sarcoma 10.4 DES WT1
43 lung combined type small cell carcinoma 10.4 CALD1 MYOG
44 liver leiomyoma 10.4 CD34 KIT
45 dedifferentiated liposarcoma 10.4 DES MDM2 TP53
46 vulvar dystrophy 10.4 CD34 PGR
47 prostate rhabdomyosarcoma 10.4 KIT MYOD1
48 female reproductive endometrioid cancer 10.4 PGR TP53 WT1
49 dysgerminoma of ovary 10.4 KIT PGR WT1
50 undifferentiated embryonal sarcoma of the liver 10.4 MDM2 MYOD1 MYOG

Graphical network of the top 20 diseases related to Muscle Cancer:



Diseases related to Muscle Cancer

Symptoms & Phenotypes for Muscle Cancer

UMLS symptoms related to Muscle Cancer:


myalgia, muscle weakness, torticollis, myoclonus, muscle spasticity, muscle rigidity, muscle cramp

MGI Mouse Phenotypes related to Muscle Cancer:

43 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.34 MB MDM2 PAX3 TP53 PGR PAX7
2 growth/size/body region MP:0005378 10.34 MYOD1 MB MYOG MDM2 PAX3 TP53
3 cardiovascular system MP:0005385 10.31 MYOD1 MDM2 PAX3 TP53 PGR WT1
4 homeostasis/metabolism MP:0005376 10.31 PAX3 MYOD1 MB MYOG MDM2 TP53
5 mortality/aging MP:0010768 10.31 MYOD1 MYOG MDM2 PAX3 PGR TFE3
6 hematopoietic system MP:0005397 10.29 MB MDM2 PAX3 TP53 PGR RHD
7 embryo MP:0005380 10.24 MYOG MDM2 PAX3 TP53 PGR PAX7
8 muscle MP:0005369 10.18 MYOG MDM2 PAX3 MYOD1 PGR WT1
9 craniofacial MP:0005382 10.15 MDM2 PAX3 TP53 TFE3 PAX7 CREB3L2
10 integument MP:0010771 10.13 MYOG MDM2 PAX3 TP53 PGR TFE3
11 neoplasm MP:0002006 10.07 MDM2 PAX3 MYOD1 PGR PAX7 TP53
12 no phenotypic analysis MP:0003012 10.06 MYOG MDM2 PAX3 MYOD1 PGR WT1
13 limbs/digits/tail MP:0005371 10 MDM2 TP53 PGR PAX3 CREB3L2 KIT
14 normal MP:0002873 10 MYOG MDM2 PAX3 MYOD1 PGR TFE3
15 respiratory system MP:0005388 9.56 PAX3 MYOD1 MB MYOG TP53 PAX7
16 pigmentation MP:0001186 9.55 MDM2 TP53 PAX3 TFE3 KIT
17 skeleton MP:0005390 9.36 MYOD1 MYOG MDM2 PAX3 TP53 PGR

Drugs & Therapeutics for Muscle Cancer

Drugs for Muscle Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 192)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
5 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
6 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
10
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
11
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
12
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
13
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
14
Morphine Approved, Investigational Phase 3,Phase 1,Phase 2 57-27-2 5288826
15
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
16
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
17
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 44424639 60780
18
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
19
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
20
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
21
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
22
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
23
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
24
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
25
Idarubicin Approved Phase 3 58957-92-9 42890
26
Mesna Approved, Investigational Phase 3,Phase 2 3375-50-6 598
27
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
28 Trofosfamide Investigational Phase 3 22089-22-1
29 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antimitotic Agents Phase 3,Phase 2,Phase 1
31 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
32 Etoposide phosphate Phase 3,Phase 2,Phase 1
33 Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
34 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
35 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
36 Antifungal Agents Phase 3,Phase 2,Phase 1
37 Bone Density Conservation Agents Phase 3,Phase 1
38 Calcium, Dietary Phase 3
39 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
40
Vinblastine Approved Phase 2 865-21-4 241903 13342
41
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
42
Melphalan Approved Phase 2,Phase 1 148-82-3 460612 4053
43
Bevacizumab Approved, Investigational Phase 2 216974-75-3
44
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
45
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
46
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
47
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
48
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
49
Etanercept Approved, Investigational Phase 2 185243-69-0
50
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741

Interventional clinical trials:

(show top 50) (show all 155)

# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
3 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00002995 Phase 3 cyclophosphamide;vincristine sulfate
4 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed NCT00354835 Phase 3 Irinotecan Hydrochloride;Cyclophosphamide;Vincristine Sulfate
5 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
6 Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma Completed NCT00003958 Phase 3 vincristine sulfate;cyclophosphamide;topotecan hydrochloride
7 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
8 Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma Recruiting NCT00876031 Phase 3 trofosfamide, idarubicin, etoposide
9 Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma Recruiting NCT02567435 Phase 3 Cyclophosphamide;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate
10 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Active, not recruiting NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
11 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma Active, not recruiting NCT00075582 Phase 3 dactinomycin;cyclophosphamide;vincristine sulfate
12 Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood Terminated NCT00162695 Phase 3 Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide
13 Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas Unknown status NCT01216839 Phase 2 Everolimus
14 Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma Unknown status NCT00245141 Phase 2 cyclophosphamide;vincristine sulfate
15 Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma Unknown status NCT00245089 Phase 2 cyclophosphamide;vincristine sulfate
16 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2 Vinorelbine, cyclofosfamide
17 Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg Completed NCT00019968 Phase 2 melphalan;tumor necrosis factor
18 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Completed NCT01222715 Phase 2 Cyclophosphamide;Temsirolimus;Vinorelbine Tartrate
19 Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Completed NCT01055314 Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Irinotecan Hydrochloride;Temozolomide;Vincristine Sulfate Liposome
20 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma Completed NCT00003955 Phase 2 cyclophosphamide;irinotecan hydrochloride;vincristine sulfate
21 Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma Completed NCT00055939 Phase 2 exatecan mesylate
22 Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma Completed NCT00025363 Phase 2 vincristine sulfate;irinotecan hydrochloride;cyclophosphamide;doxorubicin hydrochloride;ifosfamide;etoposide;tirapazamine
23 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
24 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
25 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
26 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
27 NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Completed NCT01386619 Phase 1, Phase 2
28 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01154816 Phase 2 Alisertib
29 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Completed NCT01125800 Phase 1, Phase 2 LDE225
30 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
31 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Completed NCT00070109 Phase 2 trabectedin
32 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
33 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed
34 Ixabepilone in Treating Young Patients With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
35 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
36 Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Completed NCT00309907 Phase 2 methylprednisolone
37 A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Completed NCT00001566 Phase 2 indinavir sulfate
38 A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas Completed NCT00001564 Phase 2 EF-1 Peptide;EF-2 Peptide;PXFK Peptide;E7 Peptide;IL-2;IL-4;GM-CSF;CD40 Ligand
39 Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy Completed NCT00187109 Phase 1, Phase 2 Recombinant Human Thrombopoietin
40 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
41 Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone Completed NCT00006234 Phase 1, Phase 2
42 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
43 New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma Completed NCT00001335 Phase 2 ADR-529;Topotecan;G-CSF
44 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
45 Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors Recruiting NCT03245450 Phase 1, Phase 2 Eribulin mesilate;Irinotecan hydrochloride
46 Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma Recruiting NCT03041701 Phase 1, Phase 2 Dasatinib;Ganitumab
47 Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy Recruiting NCT01871766 Phase 2 Vincristine;Dactinomycin;Cyclophosphamide;Bevacizumab;Sorafenib;Myeloid Growth Factor;Irinotecan;Ifosfamide;Etoposide;Etoposide Phosphate;Doxorubicin;Dexrazoxane;^1^1C-methionine
48 Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed Rhabdomyosarcoma Recruiting NCT01355445 Phase 2 Vincristine, Irinotecan;Vincristine, Irinotecan, Temozolomide
49 Proton RT for the Treatment of Pediatric Rhabdomyosarcoma Recruiting NCT00592592 Phase 2
50 Trial of Afatinib in Pediatric Tumours Recruiting NCT02372006 Phase 1, Phase 2 afatinib

Search NIH Clinical Center for Muscle Cancer

Cochrane evidence based reviews: myosarcoma

Genetic Tests for Muscle Cancer

Anatomical Context for Muscle Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Muscle Cancer:

18
Muscle

MalaCards organs/tissues related to Muscle Cancer:

38
Bone, Nk Cells, Bone Marrow, Myeloid, Liver, T Cells, Testes

Publications for Muscle Cancer

Articles related to Muscle Cancer:

# Title Authors Year
1
Cytotoxicity Studies of the Extracts, Fractions, and Isolated Compound of Pseudocedrela kotschyi on Cervical Cancer (HeLa), Breast Cancer (MCF-7) and Skeletal Muscle Cancer (RD) Cells. ( 28250653 )
2017
2
YAPping about differentiation therapy in muscle cancer. ( 25117705 )
2014
3
The not-so-skinny on muscle cancer. ( 23079652 )
2012
4
Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. ( 20193046 )
2010
5
A new model for muscle cancer. ( 17585343 )
2007

Variations for Muscle Cancer

Expression for Muscle Cancer

Search GEO for disease gene expression data for Muscle Cancer.

Pathways for Muscle Cancer

GO Terms for Muscle Cancer

Cellular components related to Muscle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 ASPSCR1 CREB3L2 DES EWSR1 FOXO1 MDM2
2 nucleoplasm GO:0005654 9.36 ASPSCR1 CREB3L2 FOXO1 MDM2 MYOD1 MYOG

Biological processes related to Muscle Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.92 FOXO1 MDM2 PAX7 TP53 WT1
2 transcription, DNA-templated GO:0006351 9.9 CREB3L2 EWSR1 FOXO1 MYOD1 MYOG PAX3
3 transcription by RNA polymerase II GO:0006366 9.88 CREB3L2 MYOD1 PAX3 TFE3 TP53 WT1
4 skeletal muscle tissue development GO:0007519 9.61 MYOD1 MYOG PAX7
5 muscle organ development GO:0007517 9.56 MYOD1 MYOG PAX3 PAX7
6 positive regulation of transcription, DNA-templated GO:0045893 9.56 CREB3L2 FOXO1 MYOD1 MYOG PAX3 TFE3
7 myotube differentiation GO:0014902 9.51 MYOD1 MYOG
8 positive regulation of skeletal muscle fiber development GO:0048743 9.49 MYOD1 MYOG
9 muscle cell fate commitment GO:0042693 9.48 MYOD1 MYOG
10 paracrine signaling GO:0038001 9.46 CD34 PGR
11 cellular response to actinomycin D GO:0072717 9.37 MDM2 TP53
12 positive regulation of transcription by RNA polymerase II GO:0045944 9.32 CREB3L2 FOXO1 MYOD1 MYOG PAX3 PAX7
13 regulation of transcription, DNA-templated GO:0006355 10.06 CREB3L2 EWSR1 FOXO1 MYOD1 MYOG PAX3

Molecular functions related to Muscle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.91 CREB3L2 FOXO1 MYOD1 MYOG PAX7 PGR
2 transcription regulatory region DNA binding GO:0044212 9.62 CREB3L2 TFE3 TP53 WT1
3 sequence-specific DNA binding GO:0043565 9.56 FOXO1 MYOD1 MYOG PAX3 PAX7 PGR
4 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 9.55 CREB3L2 MYOG PGR TFE3 WT1
5 DNA binding transcription factor activity GO:0003700 9.32 CREB3L2 FOXO1 MYOD1 MYOG PAX3 PAX7

Sources for Muscle Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....